Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ATRA
ATRA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ATRA News
Lisata Therapeutics to be Taken Private by Kuva Labs
1d ago
Benzinga
Atara Partners with Pierre Fabre to Address FDA Concerns on Tabelecleucel
6d ago
stocktwits
Atara Biotherapeutics Shares Rise After FDA Rejection Report
Feb 25 2026
seekingalpha
ATARA BIOTHERAPEUTICS INC - HCRX REVISITS DEADLINE FOR $9 MILLION CASH PAYMENT
Feb 23 2026
moomoo
Atara Biotherapeutics Faces Securities Fraud Investigation
Feb 13 2026
PRnewswire
Pomerantz LLP Investigates Securities Fraud Claims Against Atara Biotherapeutics
Feb 03 2026
Globenewswire
Atara Biotherapeutics Faces Securities Fraud Investigation
Jan 29 2026
PRnewswire
Atara Biotherapeutics Under Investigation After 57% Stock Drop Following FDA Response
Jan 22 2026
PRnewswire
Atara Biotherapeutics Under Investigation After 57% Stock Drop Following FDA Response
Jan 20 2026
Globenewswire
Atara Biotherapeutics' Ebvallo Receives EU Approval, Faces Second FDA Rejection
Jan 14 2026
Benzinga
Atara Biotherapeutics' EBVALLO BLA Rejected by FDA, Stock Plummets 57%
Jan 13 2026
NASDAQ.COM
Atara Biotherapeutics (ATRA) Shares Plunge 53% After FDA Issues Complete Response Letter for Tabelecleucel
Jan 12 2026
seekingalpha
Atara Biotherapeutics Faces Second FDA Rejection for EBVALLO, Shares Plunge 53%
Jan 12 2026
stocktwits
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
Jan 12 2026
Benzinga
Atara Biotherapeutics Faces FDA Rejection, Stock Plummets 52.74%
Jan 12 2026
Benzinga
Dow Jones Falls Over 250 Points as Financial Stocks Decline
Jan 12 2026
Benzinga
Show More News
